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OBJECTIVES We evaluated the effect of therapy with folic acid and cobalamin on coronary endothelial
function, expressed as a change in volumetric coronary blood flow (CBF), in hyperhomocys-
teinemic patients with coronary artery disease (CAD).
BACKGROUND Hyperhomocysteinemia is an independent risk factor for CAD. The mechanism responsible
for this increased risk is unclear, but it is generally assumed that hyperhomocysteinemia causes
endothelial dysfunction. It is unknown whether lowering plasma homocysteine levels with
folic acid and cobalamin improves coronary endothelial function in patients with hyperho-
mocysteinemia and symptomatic CAD.
METHODS Fifteen patients scheduled for elective percutaneous transluminal coronary angioplasty
(PTCA) with plasma homocysteine levels of 16 mol/l were randomized for six months of
treatment with folic acid 5 mg and cobalamin 400 g daily or placebo. Coronary endothelial
function was evaluated in a non-PTCA vessel using acetylcholine infusion in dosages of 108
M, 107 M, and 106 M. Endothelium- dependent CBF is determined using intracoronary
Doppler velocity and quantitative coronary angiography at baseline and after six months.
RESULTS In the folic acid/cobalamin treated group, CBF increased after acetylcholine infusion with
96% (standard deviation 54; 95% confidence interval [CI]: 44% to 154%) compared with a
decrease of 16% (standard deviation 35; 95% CI: 20% to 30%) of the CBF in the
placebo-treated group (p  0.005).
CONCLUSIONS This is the first prospective randomized placebo-controlled intervention study evaluating
coronary endothelial function in hyperhomocysteinemic patients with CAD. Our results
suggest that coronary endothelial function improves after treatment with folic acid and
cobalamin. (J Am Coll Cardiol 2002;40:766–72) © 2002 by the American College of
Cardiology Foundation
Hyperhomocysteinemia is an important risk factor for
premature cardiovascular disease. To date, more than 80
studies have been published about the association between
homocysteine and vascular disease (1). Homocysteine levels
can be reduced 25% to 30% using folic acid, and supple-
mentation of vitamin B12 provides an additional 7% reduc-
tion. This reduction is higher in patients with hyperhomo-
cysteinemia and patients with a low pretreatment folate
status (2). The pathophysiologic mechanisms responsible
for the increased risk remain unclear. Generally, it is
assumed that homocysteine is toxic to the vascular wall and
causes endothelial dysfunction (3). Endothelial dysfunction
is a key mechanism in the current hypothesis of athero-
thrombosis, and it is shown that functional impairment of
the endothelial function, defined as an impairment of
endothelium-dependent coronary blood flow, precedes sig-
nificant arterial vessel disease (4). Until now, it was un-
known whether homocysteine-lowering therapy would im-
prove prognosis in patients with elevated homocysteine
levels and coronary artery disease (CAD). Some investiga-
tors have shown that folic acid improves endothelial func-
tion in the forearm model in patients with CAD (5).
However, until recently, it has been unclear whether
homocysteine-lowering therapy improves coronary endo-
thelial function. The aim of this study was to evaluate the
effect of six months of therapy with folic acid 5 mg in
combination with cobalamin 400 g on coronary endothe-
lial function in patients with hyperhomocysteinemia with
symptomatic CAD.
METHODS
Patient selection. This study is a double-blind, random-
ized, placebo-controlled study with a follow-up of six
months investigating the effect of folic acid 5 mg and
cobalamin on coronary endothelial function. Cobalamin
400 g was added to avoid unopposed folic acid treatment
in undiagnosed vitamin B12 deficiency. End points were
acetylcholine (ACH)-induced changes in endothelium-
dependent coronary blood flow at baseline and after six
months of therapy. Other end points were change in mean
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segment diameter (MSD) and in minimal obstruction
diameter (MOD) of a predefined segment of a coronary
vessel after infusion of ACH.
Patients with objectively confirmed ischemic heart disease
who were referred for elective percutaneous transluminal
coronary angioplasty (PTCA) between April 1997 and June
1999 to our catheterization laboratory were eligible for this
study. Inclusion criteria were a plasma homocysteine level of
15.5 mol/l or more, age between 18 and 70 years, and at
least one coronary vessel without a significant stenosis
(stenosis 50%). Patients who used medication or vitamins
involved in homocysteine metabolism were excluded from
this study as were patients with diabetes mellitus and
patients with uncontrolled hypertension. During follow-up,
patients were asked to make no changes in their diet or
exercise levels. Patients in whom a coronary stent was placed
received 160 mg of acetylsalicylic acid instead of 80 mg
during the first month. Otherwise, the medication was kept
unchanged when possible. Patients with kidney failure
reflected as a creatinine level of more than 150 g/l or
serious liver failure were also excluded. Patients returned
after 2, 8, 12, and 23 weeks for reassessment of lipid profile,
vitamin levels, homocysteine levels, and clinical signs of
recurrent angina pectoris. The Ethical Committee of our
institution approved the protocol. Written informed con-
sent was obtained in all patients.
Coronary angiography. Long-acting nitrates were with-
drawn 24 h before the procedure and replaced by short-
acting nitrates if necessary. All procedures were performed
under the same conditions in time and location. After the
performance of the elective PTCA, a new guiding catheter
7F (Medtronic Inc., Minneapolis, Minnesota) was placed in
a nondilated coronary artery without a stenosis (50%). A
Doppler guidewire (0.014 in. diameter) (Flowire, EndoSon-
ics Inc., Pleasanton, California) within a 2.2F coronary
infusion catheter (Medtronic) was advanced in the vessel of
interest just distal to a landmark of a proximal epicardial
segment, defined as an important side-branch of a coronary
vessel, with a diameter of at least 2.0 mm. After achieving a
stable velocity signal, adenosine 18 g was administered
through the guiding catheter for maximal hyperemia, and
endothelium-independent coronary flow velocity was mea-
sured. Assessment of endothelium-dependent vasodilation
and coronary flow was performed by selective infusions of
ACH with a total amount of 108 M, 107 M, and 106M.
Acetylcholine was dissolved in NaCl 0.9% and infused with
a Terumo pump (Terumo Medical Corp., Tokyo, Japan) at
a rate of 2 ml/min during 3 min. Nitroglycerin 200 g was
then injected as a bolus.
Before infusion of ACH, baseline angiography was per-
formed using Hexabrix (Guerbet, Roissy Cedez, France)
with biplane technique. Then ACH infusion started. After
each infusion of ACH, a coronary angiography followed.
This procedure was performed at baseline and after six
months of treatment.
Assessment of coronary blood flow. Doppler flow velocity
spectra were analyzed to determine time-averaged peak
velocity. Volumetric coronary blood flow (CBF) is the
cross-sectional area  average peak velocity  0.5 (6). The
cross-sectional area is the mean area over a distance of 5 mm
in the segment 5 to 10 mm distal to the tip of the Flowire.
Endothelium-dependent coronary flow reserve is calculated
as percent change in CBF in response to ACH. Normal
coronary endothelium-dependent function is defined as an
increase of CBF of 50% or more (7). The endothelium-
independent coronary flow velocity reserve (CVR) was
calculated by dividing the average peak velocity by the
baseline average peak velocity after 18 g adenosine injec-
tion.
Quantitative coronary angiography. Analysis of baseline
and follow-up angiographies was performed using the
CAAS II QCA software (Pie Medical, Maastricht, the
Netherlands). Analysis of MOD and MSD started at an
important side-branch of the epicardial vessel and continued
until the second important side-branch of the segment.
Care was taken to ensure that the same segment of the
coronary vessel was examined at baseline and follow-up.
Therefore, the films were examined in the same session to
ensure analysis of the identical portion of the vessel. The
investigators were blinded for the treatment regimen during
analysis of the coronary angiography.
Laboratory measurements. After an overnight fasting, a
sample of venous blood was drawn on EDTA tube from the
patients and put on ice immediately. Samples were stored at
20°C and analyzed within one week. Plasma total homo-
cysteine was measured by high-performance liquid chroma-
tography. After six months a second homocysteine sample
was taken to investigate the effects of folic acid and
cobalamin on homocysteine levels. Also, samples for vita-
min analysis and lipids were analyzed at baseline and
follow-up.
Statistics. Data are expressed as mean  SD. Analysis of
baseline data was performed using chi-square test or Mann-
Whitney U test where appropriate. Response differences in
CBF, MSD, and MOD, after two subsequent amounts of
ACH infusion (107 M and 106 M), were compared in
two conditions (before treatment and after treatment) using
Abbreviations and Acronyms
ACH  acetylcholine
CAD  coronary artery disease
CBF  volumetric coronary blood flow
CI  confidence interval
CVR  coronary velocity range
LAD  left anterior descending artery
MOD  minimal obstruction diameter
MSD  mean segment diameter
PTCA  percutaneous transluminal coronary angioplasty
RCA  right coronary artery
RCX  ramus circumflexus
SD  standard deviation
tHcy  total plasma homocysteine
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a double multivariate repeated measures model (General
Linear Model, SPSS 10.1, Chicago, Illinois).
RESULTS
In the period of two years, 18 patients were recruited to the
study; 3 patients were excluded during follow-up because of
symptomatic restenosis in the PTCA vessel, 2 patients in
the folic acid group, 1 patient in the placebo group. Thus,
follow-up coronary angiography could be obtained in 15
patients, 7 patients in the folic acid group and 8 patients in
the placebo group. Two women and 13 men completed the
study. Mean age was 52.2 years (range 40 to 66 years). Of
the study group, baseline homocysteine levels were 17.9
mol/l (range 15.6 to 21.2 mol/l). Other baseline charac-
teristics of the treatment and placebo groups are listed in
Table 1. In the folic acid/cobalamin group, the right
coronary artery (RCA) was used for analysis in four patients,
the ramus circumflexus (RCX) was used in two patients, and
the left anterior descending artery (LAD) was used in one
patient. In the placebo group, the RCA was used for
analysis in four patients, the RCX was used in three
patients, and the LAD was used in one patient. No
significant differences between groups were found. In the
folic acid/cobalamin group, total plasma homocysteine
(tHcy) decreased 31.5% from 17.1mol/l (standard devia-
tion [SD] 0.91) to 11.7 mol/l (SD 1.59) (p  0.0001) as
compared with no change in the placebo-treated group. In
the folic acid/cobalamin group, plasma folic acid improved
from 11.2 nmol/l (SD 1.3) to 26.9 nmol/l (SD 3.4) (p 
0.0001), and plasma vitamin B12 improved from 415
pmol/l (SD 95) to 463 pmol/l (SD 119). No changes
occurred in the placebo-treated group. All other biochem-
ical parameters remained unchanged (Table 2). In all
patients with complete follow-up, medication during
follow-up was not changed. No significant differences in
changes in CBF, MSD, and MOD were seen at baseline
(Table 3). Changes in CBF, MSD and MOD are calculated
after the administration of the highest dosage of ACH.
Changes in CBF, MSD, and MOD after infusion of ACH
at baseline were abnormal in all patients. At follow-up, after
infusion of ACH, CBF increased in the folic acid/
cobalamin group from 39.5 ml/min (SD 15) to 77.5 ml/min
(SD 33) (p  0.01). In the placebo-treated group, CBF
decreased from 53.2 ml/min (SD 18) to 40 ml/min (SD 16)
(p  0.38). Volumetric coronary blood flow in the folic
acid/cobalamin-treated group improved 96% (SD 58) (95%
confidence interval [CI]: 44% to 154%) (p  0.05) as
compared with a decrease of 16% (SD 35) (95% CI: 20%
to 30%) (p  0.15) in the placebo-treated group. The
general linear model determined a value of p 0.005 for the
change in CBF at baseline and follow-up between the folic
acid/cobalamin group and the placebo group (Fig. 1). Mean
segment diameter decreased from 2.19 mm (SD 0.22) to
1.83 mm (SD 0.14) in the placebo-treated group and
increased from 1.99 mm (SD 0.15) to 2.12 mm (SD 0.14)
in the folic acid/cobalamin group. Mean segment diameter
decreased 16.4% in the placebo-treated group and increased
6.5% in the folic acid/cobalamin group (p  0.15) (Fig. 2).
Minimal obstruction diameter decreased from 1.76 mm
(SD 0.13) to 1.43 mm (SD 0.09) in the placebo group and
increased from 1.41 mm (SD 0.16) to 1.60 mm (SD 0.14)
in the folic acid/cobalamin group. Minimal obstruction
diameter increased 13.4% in the folic acid/cobalamin group
and decreased 18.7% in the placebo-treated group (p 
0.14) (Fig. 3). Endothelium-independent vasodilation as
presented in CVR was 2.78 (SD 0.29) at baseline in the
placebo group and 2.91 (SD 0.32) in the folic acid/
cobalamin group. In both groups, CVR did not change
significantly at follow-up.
DISCUSSION
This is the first study to observe the changes in
endothelium-dependent coronary flow in hyperhomocys-
teinemic patients with symptomatic CAD six months after
treatment with folic acid and cobalamin. This regime
significantly improved CBF, MSD, and MOD. Because
clinical trials evaluating the effect of homocysteine-lowering
therapy on clinical end points in patients with mild hyper-
homocysteinemia are not yet available, our research focused
on endothelial dysfunction as a key mechanism in
homocysteine-induced vascular disease.
Homocysteine and endothelial function. To date, angio-
graphic studies on the association between plasma homo-
cysteine levels and coronary endothelial function have not
been published, but some human studies used the reactive
hyperemia model of the brachial artery, demonstrating that
Table 1. Baseline Characteristics
Folic Acid/
Cobalamin Group
(n  7)
Placebo Group
(n  8)
p
Value*
Age (mean) (yrs) 53.4 (range 40–63) 51.3 (range 42–66) 0.54
Male/female patients 7/0 7/1 0.73
Smoking 2 1 0.44
Hypertension 1 2 0.61
Hyperlipidemia 6 6 0.61
Family history 5 2 0.07
Beta-blockers 6 8 0.27
Calcium antagonist 4 3 0.45
Nitrates 3 3 0.83
Acetylsalicylic 7 8 1.0
ACE inhibitors 1 2 0.61
Statins 4 5 0.19
Homocysteine, mol/l 17.1 (0.9)† 18.7 (2.0)† 0.15
Total cholesterol, mmol/l 6.07 (1.3) 5.56 (0.9) 0.40
HDL cholesterol, mmol/l 1.06 (0.11) 0.93 (0.19) 0.23
LDL cholesterol, mmol/l 4.29 (1.1) 3.96 (0.5) 0.61
Triglycerides, mmol/l 1.7 (0.8) 1.7 (0.5) 1.0
Folic acid, nmol/l 11.2 (1.3) 10.3 (1.4) 0.09
Vitamin B12, pmol/l 415 (95) 345 (38) 0.12
Creatinine, mol/l 93 (10) 92 (13) 0.54
*p value of chi-square test or Mann-Whitney U test was appropriate; †between
brackets: SD.
ACE  angiotensin-converting enzyme; HDL  high-density lipoprotein;
LDL  low-density lipoprotein.
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severe hyperhomocysteinemia is associated with reduced
flow-mediated vasodilation (8). Also, in patients with mild
hyperhomocysteinemia, the plasma homocysteine level was
a significant predictor of reduced flow-mediated vasodila-
tion (9,10). In the forearm model, folic acid prevented the
impairment of endothelium-dependent vasodilation after
methionine loading (11) and ameliorated endothelium-
dependent vasodilation in patients with familial hypercho-
lesterolemia and normal tHcy (12,13). However, the effect
of folic acid on endothelial function correlated with tHcy
suggesting that folic acid is more effective in patients with
high tHcy (14).
Endothelial function in epicardial vessels and resistance
vessels. Acetylcholine is widely used as a standard sub-
stance to test endothelial function in human coronary
arteries (15). In subjects with normal coronary vessels, ACH
Table 2. Changes in Risk Factors
Folic Acid/
Cobalamin Group
(n  7)
p
Value*
Placebo Group
(n  8)
p
Value*
Homocysteine, mol/l
Baseline 17.1 (0.91)† 0.0001 18.7 (1.97) 0.92
Follow-up 11.7 (1.59) 18.8 (2.21)
Serum folate, nmol/l
Baseline 11.2 (1.3) 0.0001 10.3 (1.4) 0.90
Follow-up 26.9 (3.4) 10.4 (1.3)
Vitamin B12, pmol/l
Baseline 415 (95) 0.42 346 (38) 0.98
Follow-up 463 (119) 348 (41)
Total cholesterol, mmol/l
Baseline 6.07 (1.3) 0.63 5.66 (0.9) 0.97
Follow-up 5.77 (0.9) 5.55 (0.6)
HDL cholesterol, mmol/l
Baseline 1.06 (0.12) 0.87 0.93 (0.19) 0.68
Follow-up 1.04 (0.13) 0.99 (0.19)
LDL cholesterol, mmol/l
Baseline 4.24 (1.15) 0.62 3.87 (0.69) 0.98
Follow-up 3.97 (0.81) 3.85 (0.46)
Triglycerides, mmol/l
Baseline 1.69 (0.85) 0.94 1.67 (0.34) 0.60
Follow-up 1.66 (0.72) 1.54 (0.38)
Mean arterial pressure, mm Hg
Baseline 105 (16) 0.92 111 (14) 0.68
Follow-up 107 (9) 108 (8)
*p value for difference between baseline and follow up with Mann-Whitney U test; †between brackets: standard deviation.
HDL  high-density lipoprotein; LDL  low-density lipoprotein.
Table 3. Baseline Coronary Flow Parameters After Infusion of Acetylcholine
Folic Acid/
Cobalamin Group
(n  7)
Placebo Group
(n  8) p Value
Mean change in CBF (%)
108 M 38.6 (29)* 10.8 (15) 0.051
107 M 39.2 (46) 33.1 (42) 0.79
106 M 15.6 (36) 16.3 (35) 0.96
NTG 204.3 (133) 228.7 (137) 0.73
Mean change in MSD (%)
108 M 3.5 (1.7) 1.7 (4.5) 0.64
107 M 7.6 (3.8) 11.0 (7.9) 0.06
106 M 13.9 (6.2) 12.1 (8.9) 0.08
NTG 6.1 (7.2) 8.0 (9.7) 0.39
Mean change in MOD (%)
108 M 6.7 (7.4) 8.6 (9.8) 0.40
107 M 13.4 (6.5) 13.6 (10.6) 0.28
106 M 16.2 (9.4) 18.9 (18.3) 0.37
NTG 7.0 (5.2) 4.9 (6.0) 0.02
*Standard deviation between brackets.
CBF  volumetric coronary blood flow; MOD  minimal obstruction diameter; MSD  mean segment diameter; NTG 
nitroglycerin.
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induces vasodilation of coronary vessels. In patients with
atherosclerosis, or in the presence of risk factors for vascular
disease like hypercholesterolemia, hypertension, diabetes
mellitus, and smoking, ACH has been shown to induce
paradoxical vasoconstriction (16). All patients in the study
group had severe coronary endothelial dysfunction after
infusion of ACH at baseline. Changes in MSD after
intracoronary infusion of ACH show a coronary endothelial
dysfunction expressed as a decrease in MSD at baseline.
The same is true for changes in MOD. Volumetric coronary
Figure 1. Effect of acetylcholine and nitroglycerin (NTG) on percent change in volumetric coronary blood flow in both groups. Solid diamond  baseline;
solid square  follow-up. *p  0.15 for the difference between baseline and follow-up at maximal dosage of acetylcholine (placebo group). **p  0.05 for
the difference between baseline and follow-up at the maximal dosage of acetylcholine (folic acid/cobalamin group). p  0.005 for the difference at baseline
and follow-up between the placebo group and the folic acid/cobalamin group with the general linear model.
Figure 2. Effect of acetylcholine and nitroglycerin (NTG) on percent change in mean segment diameter (MSD) in both groups. Solid diamond baseline;
solid square  follow-up. *p  0.09 for the difference between baseline and follow-up at maximal dosage of acetylcholine (placebo group). **p  0.10 for
the difference between baseline and follow-up at the maximal dosage of acetylcholine (folic acid/cobalamin group). p  0.15 for the difference at baseline
and follow-up between the placebo group and the folic acid/cobalamin group with the general linear model.
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blood flow in all patients was severely disturbed at baseline.
Follow-up demonstrated a significant improvement of CBF
in the patients who used folic acid and cobalamin. The
changes in MSD improved after infusion of ACH at
follow-up in the folic acid/cobalamin group as compared
with the placebo group. Changes in MOD improved also,
albeit not significantly.
Our patients were characterized by an abnormal response
upon ACH infusion at baseline. Because improvement of
ACH-induced vasoconstriction depends on the response at
baseline, we could expect a stronger improvement of endo-
thelial response on ACH infusion after intervention (17).
Suwaidi et al. (4) demonstrated that severe coronary
endothelial dysfunction, defined as an increase of CBF0%
after infusion of ACH, in the absence of significant CAD,
is associated with an increase in cardiac events in the
follow-up. This supports the concept that coronary endo-
thelial dysfunction is an important marker for future pro-
gression of coronary vascular disease. Assessment of CVR,
demonstrated that, in our study, all patients at baseline and
follow-up had a CVR within the normal range of 2.7 0.6,
testifying that the investigated coronary vessels at baseline
and follow-up had no significant stenosis, which could
influence changes in CBF, MSD, and MOD (18). Our
results support the hypothesis that patients with hyperho-
mocysteinemia, by using folic acid and cobalamin, might
improve their cardiovascular prognosis.
Mechanisms of endothelial dysfunction. Many observa-
tional, case-control and prospective studies have been pub-
lished on the association of hyperhomocysteinemia and
CAD (1). However, these studies cannot exclude the
possibility that hyperhomocysteinemia is rather a marker of
vascular disease than being causally related to vascular
disease. Mechanisms responsible for endothelial dysfunc-
tion in hyperhomocysteinemia are poorly understood. Sev-
eral investigators have shown that homocysteine reduces the
bioavailability of nitric oxide and enhances smooth muscle
cell proliferation, both of which are important markers of
atherothrombotic disease (3). Recently, it was hypothesized
that hyperhomocysteinemia may stimulate the formation of
asymmetrical dimethylarginine, an endogenous inhibitor of
nitric oxide synthase (19).
Folic acid and restoration of endothelial function. Folic
acid reduced homocysteine levels 25%, and the addition of
cobalamin led to a further reduction of 7% (2,20). In our
study, plasma homocysteine levels reduced 31% after six
months of treatment with folic acid 5 mg and cobalamin
400 g compared with no change in the placebo-treated
group. The mechanism responsible for the effect of folic
acid is unclear. Apart from lowering of homocysteine, folic
acid may influence endothelial function via other mecha-
nisms. Folates are also involved in endogenous restoration
of tetrahydrobiopterin, an essential cofactor for nitric oxide
synthase (21). Tetrahydrobiopterin restores endothelial
function in the forearm model in patients with hypercho-
lesterolemia (22). Other studies suggest an antioxidant effect
of folic acid (12). Improvement of endothelial function by
antioxidant supplementation has been studied before, but,
until now, the results are variable, and more extensive
Figure 3. Effect of acetylcholine and nitroglycerin (NTG) on percent change in minimal obstruction diameter (MOD) in both groups. Solid diamond 
baseline; solid square  follow-up. *p  0.06 for the difference between baseline and follow-up at maximal dosage of acetylcholine (placebo group).
**p 0.26 for the difference between baseline and follow-up at the maximal dosage of acetylcholine (folic acid/cobalamin group). p 0.14 for the difference
at baseline and follow-up between the placebo group and the folic acid/cobalamin group with the general linear model.
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studies are needed to resolve the question whether antiox-
idant therapy is useful in patients with CAD (14,23).
Also, the natural outcome of untreated homocystinuria
patients, with fasting plasma homocysteine levels 100
mol/l and a 50% risk of suffering from a vascular event
before the age of 30 years, suggests a strong effect of
homocysteine on vascular disease (24). In these patients
with severe hyperhomocysteinemia, it was demonstrated
that appropriate homocysteine-lowering therapy reduced
the risk of vascular events significantly with more than 90%
(25). Our study adds evidence to the concept that
homocysteine-lowering therapy is clinically beneficial in
patients with elevated homocysteine levels.
Study limitations. Despite the relatively small number of
patients, significant differences in coronary endothelial
function after intervention were observed in the same range
as seen in studies with cholesterol-lowering therapy. How-
ever, although this study may add evidence to the fact that
treatment of hyperhomocysteinemia may be useful in vas-
cular disease, ongoing intervention trials with clinical end
points are needed to answer the question whether treatment
of hyperhomocysteinemia indeed reduces cardiovascular
events.
Conclusions. We conclude that CBF as an expression of
coronary endothelial function improves significantly after six
months of treatment with folic acid and cobalamin in
hyperhomocysteinemic patients with symptomatic CAD.
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